secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vigil Neuroscience, Inc. (—)
CIK:        0001827087
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001193125-24-077088
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vigil Neuroscience Q4 2023 net loss $22.2M; positive Phase 2 interim data for iluzanebart; cash runway extended
--------------------------------------------------------------------------------

- Q4 2023 net loss from operations $22.2M (vs $18.5M Q4 2022); full year net loss $82.6M (vs $68.3M 2022).
- Cash, cash equivalents, and marketable securities $117.9M at Dec 31, 2023; cash runway extended into H2 2025.
- Phase 2 IGNITE trial for iluzanebart in ALSP: positive interim data showing target engagement; enrollment completed with 20 patients; next data readout Q3 2024.
- VG-3927 Phase 1 trial ongoing; interim data planned mid-2024; FDA partial clinical hold on maximum exposure limit, no expected delay.
- Appointed Petra Kaufmann, M.D., as Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/0001193125-24-077088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/d796361d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-077088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer